Covalent inhibitors targeting KRAS (G12C), present in approximately 3% of CRC patients [10], in combination with other drugs are in phase 1-3 clinical trials development [11] whereas targeted approaches of the more common KRAS mutations (e.g., G12D) and pan-(K)-RAS inhibitors are at preclinical/first-in-human stages in pan-cancer models [12, 13]. This evidence concerns the gene KRAS and cancer.